journal article·2019-09

Crystal structures of cefdinir, C 14 H 13 N 5 O 5 S 2 , and cefdinir sesquihydrate C 14 H 13 N 5 O 5 S 2 (H 2 O) 1.5

Austin M. Wheatley, James A. Kaduk, Amy M. Gindhart, Thomas N. Blanton

Powder Diffraction· Volume 34· Issue 3
Publisher page

Abstract

The crystal structures of cefdinir and cefdinir sesquihydrate have been solved and refined using synchrotron X-ray powder diffraction data, and optimized using density functional techniques. Cefdinir crystallizes in space group P2 1 (#4) with a = 5.35652(4), b = 19.85676(10), c = 7.57928(5) Å, β = 97.050(1) °, V = 800.061(6) Å 3 , and Z = 2. Cefdinir sesquihydrate crystallizes in space group C2 (#5) with a = 23.98775(20), b = 5.01646(3), c = 15.92016(12) Å, β = 109.4470(8) °, V = 1806.438(16) Å 3 , and Z = 4. The cefdinir molecules in the anhydrous crystal structure and sesquihydrate have very different conformations. The two conformations are similar in energy. The hydrogen bonding patterns are very different in the two structures, and the sesquihydrate is more stable than expected from the sum of the energies of cefdinir and cefdinir sesquihydrate, the result of additional hydrogen bonding. The powder patterns are included in the Powder Diffraction File™ as entries 00-066-1604 (cefdinir) and 00-066-1605 (cefdinir sesquihydrate).
Source: crossref · Quality: baseline

Research context

OpenAlex topics: X-ray Diffraction in Crystallography · Crystallography and molecular interactions · Crystal structures of chemical compounds

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (47)

Show source-provided references
1. Singh G. P. , Sen H. , Srivastava D. , Godbole H. M. , Singh G. P. , Mahajan P. R. , Rananaware U. B. , Nehate S. P. and Wagh S. C. (2005). “Stable Bioavailable Crystalline Form of Cefdinir and a Process for the Preparation Thereof,” US Patent Application 2005/0245738.
2. 10.1063/1.296926010.1063/1.2969260 ↗
3. Takaya T. , Takasugi H. , Magugi T. , Yamanaka H. and Kawabata K. (1985). “7-substituted-3-vinyl-3-cephem Compounds and Processes for Production of the Same,” US Patent 4,559,334.
4. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
5. 10.1107/S002188989800600110.1107/S0021889898006001 ↗
6. 10.1107/S010876819901508610.1107/S0108768199015086 ↗
7. 10.1107/S002188980100224210.1107/S0021889801002242 ↗
8. Manca S. , Sala B. and Monguzzi R. (2003). “Crystalline Form of Cefdinir,” US Patent Application 2003/0204082.
9. 10.1107/S002188980706790810.1107/S0021889807067908 ↗
10. 10.1107/S090904950801843810.1107/S0909049508018438 ↗
11. Larson A. C. and Von Dreele R. B. (2004). General Structure Analysis System, (GSAS), (Los Alamos National Laboratory Report LAUR 86-784).
12. 10.1007/BF0054909610.1007/BF00549096 ↗
13. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
14. Etudes sur la loi de Bravais
15. Bravais · 1866
16. 10.1107/S002188980201523610.1107/S0021889802015236 ↗
17. Chandrasekaran R. , Senthilkumar K. , Murugan S. , Siviah Sangaraju V. R. and Reddy O. M. (2005). “Novel Polymorph of Cefdinir,” World Patent Application WO2005/090360.
18. Kumar Y. , Prasad M. and Prasad A. (2004). “Crystalline Form of Cefdinir,” World Patent Application WO2004/104010.
19. Donnay J. D. H and Harker D. (1937). “A new law of crystal morphology extending the law of Bravais,” Am. Mineral. 22, 446–447.
20. Dandala R. and Sivakumaran M. (2005). “Novel Crystalline Form of Cefdinir,” US Patent Application 2005/0137182.
21. 10.1103/PhysRevB.70.11511110.1103/PhysRevB.70.115111 ↗
22. 10.1002/anie.19951555110.1002/anie.199515551 ↗
23. 10.1021/op060106010.1021/op0601060 ↗
24. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
25. Open babel: an open chemical toolbox
26. 10.1107/S002188989400421810.1107/S0021889894004218 ↗
27. 2013
28. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
29. 10.1017/S088571561700028810.1017/S0885715617000288 ↗
30. 10.1021/ar00172a00510.1021/ar00172a005 ↗
31. Wavefunction, Inc. (2017). Spartan ‘16 Version 2.0.1, Wavefunction Inc., 18401 Von Karman Ave., Suite 370, Irvine CA 92612.
32. Turner M. J. , McKinnon J. J. , Wolff S. K. , Grimwood D. J. , Spackman P. R. , Jayatilaka D. and Spackman M. A. (2017). CrystalExplorer17 (University of Western Australia): http://hirshfeldsurface.net.
33. Sun S. , Liu W. and Feng C. (2015). “A new crystal form and preparation method Cefdinir,” Chinese patent application CN 103467494 B.
34. 10.1016/0927-0256(96)00008-010.1016/0927-0256(96)00008-0 ↗
35. Duerst R. W. , Law D. and Lou X. (2005). “Polymorph of a Pharmaceutical,” US Patent Application 2005/0059818.
36. 10.1107/S205252061800233010.1107/S2052520618002330 ↗
37. 10.1063/1.46788210.1063/1.467882 ↗
38. 10.1021/ci049780b10.1021/ci049780b ↗
39. 2017
40. Law D. , Henry R. F. and Lou X. (2005). “Trihemihydrate, Anhydrate and Hydrate Forms of Cefdinir,” World Patent Application WO2005/090361.
41. 2018
42. 10.1017/S088571561800082910.1017/S0885715618000829 ↗
43. Ohnishi N. , Deguchi S. and Kitamura S. (2008). “Oral Pharmaceutical Suspension of Cefdinir Crystal,” US Patent 7,351,419.
44. Daemon O. , Hartmann K. and Raneburger J. (2006). “Crystalline cefdinir,” U.S. Patent Application 11/294,116.
45. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
46. 10.1107/S002188988708709010.1107/S0021889887087090 ↗
47. 10.1002/qua.2465810.1002/qua.24658 ↗